prodchem
Jul 10, 2026
Per- and polyfluoroalkyl substances (PFAS), often referred to as "forever chemicals," have become one of the most significant environmental and regulatory issues facing global industries. Recent litigation involving 3M has intensified scrutiny over how PFAS-related information was managed and disclosed. Government claims allege that important information regarding PFAS risks was withheld over several decades, allegations that 3M has disputed while continuing to address regulatory and legal proceedings.
For pharmaceutical manufacturers and procurement teams, the litigation extends beyond legal headlines. It highlights the growing importance of chemical transparency, supplier due diligence, regulatory compliance, and long-term supply chain risk management. As environmental regulations evolve, buyers of pharmaceutical raw materials and manufacturing inputs must better understand how PFAS-related developments could influence sourcing decisions.
PFAS are a large family of synthetic chemicals valued for their resistance to heat, water, oil, and chemicals. Their unique performance characteristics have led to widespread industrial use for decades.
Within the pharmaceutical sector, PFAS may be involved in:
Specialized manufacturing equipment
Laboratory consumables
Filtration systems
Certain processing aids
Protective coatings
Packaging applications used in pharmaceutical manufacturing
While many pharmaceutical products do not intentionally contain PFAS, manufacturers may encounter PFAS within broader supply chains and production infrastructure.
The legal actions involving 3M center on allegations that information concerning PFAS contamination and potential environmental impacts was not fully disclosed to regulators and the public over many years. The company has faced numerous lawsuits from U.S. states, municipalities, and other parties related to PFAS contamination of water supplies and environmental remediation.
Although individual legal proceedings continue, the broader implications extend beyond any single company. Regulators worldwide are increasing their focus on PFAS production, usage, reporting requirements, and environmental accountability.
For procurement professionals, the litigation reinforces the importance of monitoring supplier compliance, chemical disclosures, and evolving regulatory obligations rather than focusing solely on product pricing.
The pharmaceutical industry operates under strict quality and regulatory standards. As environmental regulations become more comprehensive, procurement teams must consider both direct and indirect PFAS-related risks.
Buyers may request greater transparency regarding raw materials, processing chemicals, manufacturing practices, and environmental compliance throughout the supply chain.
Growing PFAS regulations across multiple jurisdictions may introduce new reporting requirements, product restrictions, or documentation expectations for manufacturers and suppliers.
Suppliers affected by PFAS remediation costs, legal liabilities, or production changes may experience operational disruptions that influence availability and pricing.
Healthcare organizations increasingly evaluate suppliers using environmental, social, and governance (ESG) criteria. Demonstrating responsible sourcing practices can strengthen stakeholder confidence.
Rather than reacting only after regulations change, procurement teams can proactively strengthen supply chain resilience.
Recommended actions include:
Expand supplier qualification processes to include environmental compliance, chemical management programs, and sustainability practices.
Maintain clear documentation regarding raw material composition, supplier declarations, and applicable regulatory certifications.
Reducing dependence on a single supplier or region can improve resilience if regulatory actions affect production capacity.
Track PFAS-related regulations across major pharmaceutical markets to anticipate changes that could influence sourcing strategies.
Procurement, quality assurance, regulatory affairs, environmental health and safety (EHS), and legal teams should work together to assess emerging compliance risks.
The 3M litigation reflects a wider shift toward greater transparency and accountability in chemical manufacturing. Governments are strengthening oversight of substances with potential environmental and health impacts, while companies face increasing expectations to provide comprehensive information about their products and manufacturing processes.
For pharmaceutical manufacturers, this trend reinforces the importance of integrating environmental considerations into supplier selection, contract management, and long-term procurement planning.
Organizations that invest early in supplier transparency and regulatory preparedness are likely to adapt more effectively as PFAS policies continue to evolve.
PFAS regulation is expected to remain a priority for regulators around the world. Additional reporting requirements, restrictions on certain PFAS substances, and expanded environmental monitoring may continue to shape chemical supply chains over the coming years.
Pharmaceutical buyers should view these developments not simply as compliance challenges but as opportunities to strengthen supply chain visibility, improve risk management, and build more resilient sourcing strategies.
The ongoing 3M PFAS litigation highlights the increasing importance of chemical transparency, regulatory compliance, and environmental stewardship across global supply chains. While the legal proceedings focus on specific allegations and remain subject to judicial outcomes, the broader lesson for pharmaceutical procurement is clear: supply chain visibility and proactive risk management are becoming essential business capabilities.
By strengthening supplier due diligence, improving material traceability, monitoring regulatory developments, and collaborating across compliance functions, pharmaceutical organizations can better navigate evolving PFAS regulations while maintaining reliable access to critical manufacturing inputs.
Featured Product
Found this useful?
Continue Reading
Scope 3 emissions have become a strategic priority for chemical manufacturers, traders and procurement teams. Understand value chain accounting, supplier engagement and practical approaches to reducing emissions across global chemical supply chains.
The revised Corporate Sustainability Reporting Directive (CSRD) significantly narrows the number of companies required to publish mandatory sustainability reports. For chemical procurement professionals, the most important implication is not simply who leaves the reporting scope—but how buyers should continue collecting supplier ESG information from companies no longer subject to mandatory disclosure.
For most chemical companies, the largest share of greenhouse gas emissions does not originate inside their own facilities. Instead, it occurs across the wider value chain. Understanding why Scope 3 emissions dominate the sector helps procurement professionals focus ESG efforts where they can have the greatest long-term impact.
